Participant flow and baseline characteristics.
TB, hepatitis B, infection, infectious disease, hepatitis A, typhoid
HEPATITIS B, EVENT, TUBERCULOSIS, INFECTION, INFECTIOUS DISEASE, HEPATITIS A, TYPHOID, YELLOW FEVER, RABIES
Between 24 March and 23 April 2020, 1,526 HCWs were screened and 1,511 were randomized, with 753 HCWs in the BCG group and 758 in the placebo group (BCG-Corona Study flow. Footnotes: (1) The first participant was enrolled on 24 March 2020 and the last participant on 23 April 2020. The last day of follow-up in the app was 27 March 2021, with additional participant information obtained via an online questionnaire to cover the period between 28 March 2021 and the last blood sampling date, if applicable. (2) Thirteen participants were not eligible: pregnancy (Completeness of smartphone diary application entries by all randomized participants (The majority of the 1,309 participants (74.4%) were female, with no difference between groups (Time-to-first event curves. Footnotes: (1) Self-reported episodes included proven episodes with and without seroconversion. (2) Sero-identified episodes included all possible episodes detected through serology that could be linked to a symptomatic period and therefore had a known episode infection date. (3) WHO mild episodes were further subcategorized into very mild and mild episodes (definitions can be found in Baseline characteristics of the analysis population by study groupChi-squared tests for categorical variables and Wilcoxon rank sum test for continuous variables.The 1.42 years difference in mean age was statistically significant, but we believe that it was not relevant in this context.Internal medicine includes the pulmonology and infectious disease departments.Tuberculosis tests included the Mantoux and/or TB QuantiFERON tests.The following other vaccinations were reported: diphtheria-tetanus-pertussis-polio (DTaP-IPV), hepatitis A, hepatitis B, yellow fever, typhoid, rabies, mumps-measles-rubella, meningococcal, pneumococcal, In the Netherlands, the SARS-CoV-2 vaccines available during the study period were Spikevax (Moderna Biotech, Cambridge, MA, USA), Comirnaty (Pfizer/BioNTech, New York, NY, USA), Vaxzevria (AstraZeneca AB, Sodertalje, Sweden), and Jcovden (Janssen Vaccines, Leiden, Netherlands). In addition, one participant received an experimental vaccine by CureVac N.V. in a clinical trial setting. This vaccine was never marketed due to insufficient efficacy. See Baseline characteristics of the randomized population (A) and of core hospitals versus other hospitals (B). Download 